Home Newsfeeds Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

News

Elastic Signs Strategic Collaboration Agreement With AWS To Accelerate Generative AI Solutions

By Benzinga Newsdesk

November 16, 10:18 AM

Strategic Collaboration Agreement makes it easier for customers to build and scale generative AI-powered applicationsElastic (NYSE:ESTC) ("Elastic"), the company behind Elasticsearch®, today announced a new two-year

AMZN

Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying

By Lisa Levin

January 19, 10:04 AM

The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

CNTX